TownSquare Capital’s Neuropace NPCE Stock Holding History

TownSquare Capital’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,859	Closed	-$164K	–	1281
2023 Q4	$164K	Buy	+15,859	New	+$126K	﹤0.01%	1075

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

KLC

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TownSquare Capital's NPCE Position: Q1 2024 in Review

TownSquare Capital sold out of Neuropace (NPCE) in Q1 2024, closing a stake of 15,859 shares — an estimated $164K sold.

TownSquare Capital first reported a position in NPCE in Q4 2023 and held it in 1 quarter. The position peaked at $164K in Q4 2023. 54 funds tracked by Wall St. Rank hold NPCE as of Q1 2024.

TownSquare Capital reported no remaining Neuropace position as of Q1 2024 after selling out during the quarter.
TownSquare Capital sold 15,859 Neuropace shares in Q1 2024, an estimated $164K.
TownSquare Capital first reported a position in Neuropace in Q4 2023 and held it in 1 quarter.
TownSquare Capital's Neuropace position peaked at $164K in Q4 2023.
54 funds tracked by Wall St. Rank held Neuropace as of Q1 2024.

Based on TownSquare Capital's 13F filing for Q1 2024, filed 15 May 2024.